Akeso
Akeso, Inc., a leading biopharmaceutical company headquartered in China (CN), is renowned for its innovative approach in the fields of oncology and autoimmune diseases. Founded in 2007, Akeso has rapidly established itself as a key player in the biopharma industry, with a strong focus on the research, development, and commercialisation of monoclonal antibodies and bispecific antibodies. With major operational regions across Asia and expanding into global markets, Akeso's core products include its proprietary therapies that target various cancers and immune disorders. The company is distinguished by its commitment to advancing biologics, leveraging cutting-edge technology to enhance treatment efficacy. Notably, Akeso has achieved significant milestones, including successful clinical trials and partnerships that bolster its market position, making it a formidable contender in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Akeso's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso's score of 26 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akeso's reported carbon emissions
In 2023, Akeso reported total carbon emissions of approximately 28,229,430 kg CO2e, with Scope 1 emissions at about 1,397,580 kg CO2e and Scope 2 emissions at approximately 26,831,850 kg CO2e. This marks an increase from 2022, when total emissions were about 23,740,020 kg CO2e, with Scope 1 emissions of approximately 82,000 kg CO2e and Scope 2 emissions of about 23,658,020 kg CO2e. Over the past few years, Akeso has demonstrated a commitment to reducing its carbon footprint. In 2021, the company reported total emissions of approximately 4,530,880 kg CO2e, with Scope 1 emissions at about 35,230 kg CO2e and Scope 2 emissions at approximately 4,495,650 kg CO2e. In 2020, total emissions were around 4,174,020 kg CO2e, indicating a significant reduction from 2021 to 2022. Despite these fluctuations, Akeso has not disclosed specific reduction targets or initiatives as part of its climate commitments. The company has focused on transparency in its emissions reporting, covering Scope 1 and Scope 2 emissions, but has not provided data on Scope 3 emissions. Overall, Akeso's emissions data reflects its ongoing efforts to monitor and manage its carbon footprint, although further details on reduction strategies and long-term commitments are not currently available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 44,390 | 00,000 | 00,000 | 0,000,000 |
| Scope 2 | 4,129,630 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
